Yan Shu, Xue Shuyu, Wang Tiantian, Gao Ruihang, Zeng Hanqiao, Wang Qianmeng, Jia Xiaojing
Department of Tumor Radiotherapy, The Second Hospital of Jilin University, Changchun, China.
Front Oncol. 2023 Aug 10;13:1086214. doi: 10.3389/fonc.2023.1086214. eCollection 2023.
Nintedanib is a tyrosine kinase inhibitor of fibroblast growth factor-, vascular endothelial growth factor-, and platelet-derived growth factor receptors. These three receptors promote new blood vessel formation and maintenance, which is essential for tumor growth and spread. Several trials have shown that nintedanib plays a substantial role in treating patients with non-small cell lung cancer (NSCLC) and idiopathic pulmonary fibrosis. Recently, several clinical trials of nintedanib to treat NSCLC have been reported. In this review, we focus on our current understanding of nintedanib treatment for advanced NSCLC patients and summarize the literature on using nintedanib in radiation-induced lung toxicity and the efficacy and tolerability of nintedanib.
尼达尼布是一种成纤维细胞生长因子受体、血管内皮生长因子受体和血小板衍生生长因子受体的酪氨酸激酶抑制剂。这三种受体促进新血管的形成和维持，而这对于肿瘤的生长和扩散至关重要。多项试验表明，尼达尼布在治疗非小细胞肺癌（NSCLC）和特发性肺纤维化患者方面发挥着重要作用。最近，已有多项关于尼达尼布治疗NSCLC的临床试验报道。在本综述中，我们重点阐述了目前对尼达尼布治疗晚期NSCLC患者的认识，并总结了有关尼达尼布在放射性肺损伤中的应用以及尼达尼布的疗效和耐受性的文献。
